A Postdoc position is a available in a joined project of the Research Groups of Dr. Armin Rehm (Translational Tumorimmunology) and PD Dr. Uta E. Höpken (Microenvironmental Regulation of Autoimmunity and Cancer).
Our laboratories develop experimental models to mimic human leukemia and lymphoma. We have unraveled mechanisms that cause leukemia and lymphoma to be addicted to the local microenvironment by combining animal models, molecular biology approaches, microscopic imaging and genomics methodologies (i.e.; Heinig et al., Cancer Discovery 2014; Rehm et al., Nature Communications 2014; Stache et al, Oncoimmunology 2017; Gätjen et al., Cancer Research 2016; Gloger et al, Cancer Research 2020).
Studying cell biological mechanisms that define the capacity of T cells to mediate protection from infections or tumors, we have identified gene functions that amplify secretion of effector molecules. Our strategies to boost T cell avidity and thus, improve Adoptive T Cell Therapy (ACT) converge at the final steps of effector functions. We combine the regulation of T cell cytolytic capacity with strategies to target lymphoma and leukemia therapeutically. We have generated chimeric antigen receptor (CAR) T cells that target novel tumor-associated antigens in lymphoma, and we validate them for clinical translation (Bluhm et al., Molecular Therapy 2018).
The tasks of the Postdoc Scientist will be the generation and in vitro and in vivo characterization of new generation CAR- and TCR-T cell products with an enhanced cytolytic activity. An MDC proprietary technology will be employed that regulates the capacity of transgenic human T cells to release effector molecules. This technology will be combined with CARs and TCRs directed against surface antigens displayed on hematological tumors. A special focus will be the assessment of the toxicology and secondary pharmacology of the products. Retro- and lentiviral transduction protocols for human T cells will be used, non-viral delivery methods are also expected to be implemented. Tasks will include the preparation of GLP- and GMP-compliant protocols, which are suitable for transfer to CMOs and GMP facilities. Filing of protocols, SOPs, briefing documents suitable for submission to Paul-Ehrlich-Institute (PEI) scientific advisory meetings are expected. Participation in GMP and GLP training courses will be offered.
We are looking for enthusiastic and ambitious PhDs who have, as an obligatory requirement, acquired extensive experiences in molecular biology, tumor immunology, and animal experimentation. Prior experiences in viral- and/or non-viral T cell transduction methods are advantageous.
Strong interest in tumor immunotherapy is required. Candidates should have excellent interpersonal and communication skills. They should submit a CV, a resume of their previous research accomplishments, names of 2 referees, and a motivation letter.
The MDC is committed to diversity and actively supports equal opportunities for all employees regardless of their origin, religion, ideology, disability, age or sexual identity. Applications from women are explicitly encouraged. Severely disabled persons will be given preferential treatment in the case of equal qualification
Equivalent to TVöD-O E13
This is a temporary Maternity Leave Position, funding is provided initially for 13 months, extension is possible for another 1 year.
Dr. Armin Rehm, Max-Delbrück-Center for Molecular Medicine
Robert-Rössle-Str. 10, D-13125 Berlin; email@example.com
Phone: +49-30-9406 3817
PD Dr. Uta E. Höpken, Max-Delbrück-Center for Molecular Medicine
Robert-Rössle-Str. 10, D-13125 Berlin; firstname.lastname@example.org
Phone: +49-30-9406 3330